Bryan H. Louie

Bryan H. Louie

Auto-generated profile, based on publicly available information

Bryan H. Louie

Division of Interventional Radiology, Department of Radiology, University of California San Diego, San Diego, California

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2018 in Science
Verified
Journal Article
Closed access
PDF file
MCM. Ryan Corces
M. Ryan Corces
JGJeffrey M. Granja
Jeffrey M. Granja
SSShadi Shams
Shadi Shams
BLBryan H. Louie
Bryan H. Louie
JSJose A. Seoane
Jose A. Seoane
HCHoward Y. Chang
Howard Y. Chang
Cancer chromatin accessibility landscape: The Cancer Genome Atlas (TCGA) provides a high-quality resource of molecular data on a large variety of human cancers. Corces et al. used a recently modified assay to profile chromatin accessibility to determine the accessible chromatin landscape in 410 TCGA samples from 23 cancer types (see the Perspective by Taipale). When the data were integrated with other omics data available for the same tumor samples, inherited risk loci for cancer predisposition were revealed, transcription factors and enhancers driving molecular subtypes of cancer with patient survival differences were identified, and noncoding mutations associated with clinical prognosis were discovered. Science , this issue p. eaav1898 ; see also p. 401

20 August 2020 in Cancer Treatment Reviews
Verified
Journal Article
Open access
BLBryan H. Louie
Bryan H. Louie
RKRazelle Kurzrock
Razelle Kurzrock
BRCA1-Associated Protein 1 (BAP1) is a ubiquitin carboxy-terminal hydrolase that has been established as a tumor suppressor, utilizing its deubiquitinating activity to regulate a number of processes including DNA damage repair, cell cycle control, chromatin modification, programmed cell death, and the immune response. Mutations in the BAP1 gene commonly result in a number of aggressive cancers; predominantly uveal melanoma, malignant mesothelioma, renal cell carcinoma, and cutaneous melanoma. Importantly, germline mutations in the BAP1 gene have been established as a novel tumor predisposition syndrome, conferring an increased risk of hereditary, early-onset cancers. Current treatment options for cancers with BAP1 alterations are limited to standard therapies. However, several therapeutic avenues have been proposed to specifically target BAP1 alterations in cancer. Molecularly targeted approaches include histone deacetylase inhibitors and EZH2 inhibitors to target the role of BAP1 in chromatin modification and transcriptional regulation, respectively. PARP inhibitors and platinum chemotherapy agents have the potential to target BAP1-altered tumors, due to the role of BAP1 in DNA damage repair. Lastly, emerging reports suggest that BAP1-alterations in cancer confer distinct immunogenic phenotypes that may be particularly susceptible to novel cancer immunotherapies. This review aims to present a concise and up to date report on the BAP1 gene in cancer, surveying its functional roles, characteristics and clinical manifestations. Furthermore, we highlight the established and emerging therapeutic options for BAP1-mutated cancers.

27 May 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MMMaxwell R. Mumbach
Maxwell R. Mumbach
JGJeffrey M. Granja
Jeffrey M. Granja
RFRyan A. Flynn
Ryan A. Flynn
CRCaitlin M. Roake
Caitlin M. Roake
ASAnsuman T. Satpathy
Ansuman T. Satpathy
HCHoward Y. Chang
Howard Y. Chang

8 April 2022 in Molecular Oncology
Verified
Journal Article
Open access
BLBryan H. Louie
Bryan H. Louie
SKShumei Kato
Shumei Kato
KKKi Hwan Kim
Ki Hwan Kim
HLHyo Jeong Lim
Hyo Jeong Lim
SLSuzanna Lee
Suzanna Lee
RKRazelle Kurzrock
Razelle Kurzrock
Treatment for advanced colorectal cancer is often limited by complex molecular profiles, which promote resistance to systemic agents and targeted monotherapies. Recent studies suggest that a personalized, combinatorial approach of matching drugs to tumor alterations may be more effective. We implemented a precision medicine strategy by forming a Molecular Tumor Board (MTB), a multidisciplinary team of clinicians, scientists, bioinformaticians and geneticists. The MTB integrated molecular profiling information and patient characteristics to develop N‐of‐One treatments for 51 patients with advanced colorectal cancer. All patients had metastatic disease and 63% had received ≥ 3 prior therapy lines. Overall, 34/51 patients (67%) were matched to ≥ 1 drug recommended by the MTB based on individual tumor characteristics, whereas 17/51 (33%) patients received unmatched therapies. Patients who received matched therapy demonstrated significantly longer progression‐free survival (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.21–0.81;P = 0.01) and a trend towards higher clinical benefit rates (41% vs. 18%,P = 0.058) (all multivariate) compared to patients receiving unmatched therapy. The MTB facilitated personalized matching of drugs to tumor characteristics, which was associated with improved progression‐free survival in patients with advanced colorectal cancer.

22 September 2022 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
BLBryan H. Louie
Bryan H. Louie
SKShumei Kato
Shumei Kato
KKKi Hwan Kim
Ki Hwan Kim
HLHyo Jeong Lim
Hyo Jeong Lim
RORyosuke Okamura
Ryosuke Okamura
RKRazelle Kurzrock
Razelle Kurzrock
Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics to develop N-of-One therapies for patients in the pan-cancer, advanced, refractory setting. This study evaluates the experience of 80 patients who were presented to the MTB and received a treatment regimen that included ICB. Overall, 60/80 patients (75%) who received ICB following MTB discussion had a high degree of matching between tumor molecular characteristics, including ICB biomarkers (reflected by a high Matching Score (≥50%)) and therapy administered. Patients with high versus low Matching Score experienced significantly longer median progression-free survival (6.4 vs. 3.0 months; p = 0.011) and median overall survival (15.3 vs. 4.7 months; p = 0.014) and higher clinical benefit rates (stable disease ≥6 months/partial response/complete response) (53% vs. 21%, p = 0.019). Although most patients (52/80 (65%)) received a personalized combination therapy (e.g., targeted, hormonal, chemotherapy, or a second immunotherapy agent), administering >1 drug was not associated with outcome. Only degree of matching and age, but no other variables, including individual biomarkers (e.g., microsatellite status, tumor mutational burden, or PD-L1 status), were independently correlated with outcome. In the pan-cancer setting, the MTB facilitated a precision medicine strategy to match therapeutic regimens that included ICB alone or combined with matched targeted drugs to patients with advanced malignancy, which was associated with improved clinical outcomes.

5 July 2024 in iScience
Verified
Journal Article
Open access
BLBryan H. Louie
Bryan H. Louie
SKShumei Kato
Shumei Kato
JLJordan S. Lim
Jordan S. Lim
KKKi Hwan Kim
Ki Hwan Kim
HLHyo Jeong Lim
Hyo Jeong Lim
RKRazelle Kurzrock
Razelle Kurzrock
Treatment of rare/ultra-rare tumors is an unmet need due to a lack of standardized therapies and clinical trials. We developed the Molecular Tumor Board (MTB), a multidisciplinary team that integrates molecular profiling to generate personalized, N-of-One treatments for advanced cancers. This study evaluates 112 patients with rare/ultra-rare tumors who presented to the MTB and were evaluable for clinical therapeutic outcome. Overall, 46/112 patients (41%) received a treatment regimen with a high degree of matching between tumor molecular alterations and drugs given (reflected by a high Matching Score (≥50%)). Patients with a high versus low Matching Score experienced significantly longer progression-free survival (p = 0.005) and overall survival (p = 0.047), and higher rates of clinical benefit (stable disease ≥6 months, partial response, or complete response) (54% vs. 32% p = 0.027). The MTB facilitated personalized N-of-One matching of drugs to tumor molecular alterations, which was associated with improved clinical outcomes in patients with rare/ultra-rare cancers.